TABLE 1.
Characteristic | No. of patients | % |
---|---|---|
Sex | ||
Male | 46 | 92 |
Female | 4 | 8 |
Primary tumor site | ||
Tonsil | 19 | 38 |
Base of tongue | 25 | 50 |
Unknown | 3 | 6 |
Hypopharynx | 1 | 2 |
Larynx | 1 | 2 |
Nasopharynx | 1 | 2 |
T classification | ||
T0 | 3 | 6 |
T1 | 15 | 30 |
T2 | 26 | 52 |
T3 | 4 | 8 |
T4 | 2 | 4 |
N classification | ||
N1 | 4 | 8 |
N2a | 2 | 4 |
N2b | 34 | 68 |
N2c | 8 | 16 |
N3 | 2 | 4 |
HPV | ||
Positive | 46 | 92 |
Negative (p16+) | 4 | 8 |
FNA | ||
No | 21 | 42 |
Yes | 29 | 58 |
Chemotherapy | ||
CDDP | 43 | 86 |
None | 2 | 4 |
Other* | 5 | 10 |
Abbreviations: HPV, human papillomavirus; FNA, fine-needle aspiration; CDDP, cis-diamminedichloroplatinum.
3, 1, 1 patients received concomitant carboplatin, erbitux or carboplatin + taxol, respectively.